UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
The number of shares and votes in Orexo AB (STO:ORX) have changed as a result of that the company has repurchased the entire issue of class C shares.
Today, the last trading day of the month, there are in total 34,580,810 shares - whereof 34,445,810 are ordinary shares and 135,000 class C shares - and 34,459,310 votes in the company.
About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.
For information about Orexo please visit www.orexo.com
This information was brought to you by Cision http://news.cision.com
Contacts
Orexo AB
Henrik Juuel
EVP and Chief Financial Officer
Tel: +46 (0)18-780 88 00
E-mail: ir@orexo.com
Help employers find you! Check out all the jobs and post your resume.
